EMA Authorised: Elzonris (tagraxofusp) — Stemline Therapeutics B.V.

View source ↗

Summary

The EMA authorised Elzonris (tagraxofusp) for a lymphoma indication and designated it as an orphan medicine (decision date 17 September 2025).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Drugs mentioned

• Elzonris (tagraxofusp)

Snippet

Status: Authorised. Therapeutic area: Lymphoma. MAH: Stemline Therapeutics B.V.. Decision date: 17/09/2025. Orphan medicine